MRC1 and glioblastoma: Previous studies have reported a trend towards increased numbers of CD8+ T cells in glioblastomas with deficient MMR (dMMR) (19, 20), suggesting the potential to convert a “cold” TIME into a “hot” phenotype, which may enhance the effectiveness of immunotherapies.